GSK is back on level pegging with its rivals in the RSV vaccine category in the US, after getting FDA approval for Arexvy in the 18 to 49 age bracket.

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844